We next applied TARGET-seq to analyze 458 HSPCs in samples from five patients with myeloproliferative neoplasms (MPN); the samples carried different combinations of JAK2V617F, EZH2, and TET2 mutations (Tables 1 and S3). This evidence concerns the gene EZH2 and myeloproliferative disorder.